Lenvatinib primarily targets VEGFR and FGFR family members and, to a lesser extent, RET and KIT and is approved as monotherapy for the treatment of hepatocellular carcinoma and differentiated thyroid cancer [41, 42]. This evidence concerns the gene RET and hepatocellular carcinoma.